GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Last trade$17.95
Day change-$0.80 (-4.27%)
Day range$17.61 – $18.91
Volume245,845
Market cap$1.29B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for GHRS.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for GHRS.
Recent news
Company coverage with links to the original publishers.
Five psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.
U.S. stock futures rose on Monday as major indices opened the first full trading week of 2026 higher. Following the U.S. strike on Venezuela and removal of President Maduro, crude oil prices fluctuated around $57.29 per barrel. Several stocks gained attention: Vertiv Holdings jumped on an upgrade, GH Research soared on FDA update news, Nukkleus rose after acquiring Israeli defense software, Ironwood advanced on positive FY26 guidance, and Brand Engagement Network climbed on a new vendor agreement. JPMorgan's outlook suggests continued but challenged strength in U.S. equities, with potential 10-15% corrections offset by year-end gains driven by AI-related spending.
GH Research announced presentation of long-term clinical data on GH001, a potential treatment for treatment-resistant depression, at the 38th Annual European College of Neuropsychopharmacology Congress in Amsterdam.
GH Research submitted a complete response to FDA's clinical hold on GH001, with one remaining issue regarding respiratory tract histology in rats. The Phase 2b trial showed a 73% remission rate at 6 months for treatment-resistant depression, with no serious adverse events and promising treatment outcomes.
GH Research PLC, a clinical-stage biopharmaceutical company, announced the submission of its complete response to the FDA regarding the clinical hold on its Investigational New Drug Application for GH001, its lead product candidate for treating treatment-resistant depression.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.